Mealey's (March 17, 2022, 1:19 PM EDT) -- WASHINGTON, D.C. — The Federal Circuit U.S. Court of Appeals’ finding that two genus cholesterol drug patents of Amgen Inc. were invalid for lack of enablement comports with statutory law and case law, Sanofi argues in a March 14 brief opposing Amgen’s petition for certiorari, telling the U.S. Supreme Court that, despite the arguments of the petitioner and its amici, the ruling did not create a new standard for determining enablement....